---
title: 'Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death:
  Insights from the AEGIS-II Trial'
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38588930/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240409180714&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: While CSL112 did not significantly reduce the occurrence
  of the primary study endpoints, patients treated with CSL112 infusions had numerically
  lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared
  to placebo. These findings could suggest a role of apoA-I in reducing subsequent
  plaque disruption events via enhanced cholesterol efflux. Further prospective data
  would be needed to confirm these ...'
disable_comments: true
---
CONCLUSION: While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these ...